OP Asset Management Ltd Takes $1.87 Million Position in Zimmer Biomet Holdings, Inc. $ZBH

OP Asset Management Ltd acquired a new position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) in the first quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 20,650 shares of the medical equipment provider’s stock, valued at approximately $1,867,000.

Several other large investors have also made changes to their positions in the company. Mitsubishi UFJ Asset Management Co. Ltd. lifted its stake in shares of Zimmer Biomet by 6.1% in the 3rd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 399,826 shares of the medical equipment provider’s stock valued at $39,383,000 after purchasing an additional 22,992 shares in the last quarter. Inceptionr LLC acquired a new stake in Zimmer Biomet during the 3rd quarter worth approximately $1,217,000. PNC Financial Services Group Inc. raised its holdings in Zimmer Biomet by 9.4% in the fourth quarter. PNC Financial Services Group Inc. now owns 161,195 shares of the medical equipment provider’s stock valued at $14,495,000 after buying an additional 13,883 shares during the period. Wilsey Asset Management Inc. purchased a new position in shares of Zimmer Biomet in the 4th quarter valued at $32,439,000. Finally, Dimensional Fund Advisors LP raised its position in Zimmer Biomet by 1.8% in the third quarter. Dimensional Fund Advisors LP now owns 2,269,122 shares of the medical equipment provider’s stock valued at $223,503,000 after purchasing an additional 39,146 shares during the period. 88.89% of the stock is owned by hedge funds and other institutional investors.

Zimmer Biomet Stock Performance

Shares of NYSE ZBH opened at $92.92 on Monday. The company has a quick ratio of 0.95, a current ratio of 1.73 and a debt-to-equity ratio of 0.50. The firm’s 50-day moving average price is $86.78 and its two-hundred day moving average price is $89.97. Zimmer Biomet Holdings, Inc. has a 52-week low of $79.12 and a 52-week high of $108.29. The stock has a market capitalization of $17.98 billion, a P/E ratio of 24.14, a P/E/G ratio of 2.74 and a beta of 0.47.

Zimmer Biomet (NYSE:ZBH) last posted its earnings results on Tuesday, April 28th. The medical equipment provider reported $2.09 EPS for the quarter, beating the consensus estimate of $1.86 by $0.23. The company had revenue of $2.09 billion during the quarter, compared to analyst estimates of $2.07 billion. Zimmer Biomet had a return on equity of 13.24% and a net margin of 9.05%.The business’s revenue was up 9.3% compared to the same quarter last year. During the same period in the prior year, the company earned $1.81 earnings per share. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. As a group, sell-side analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.49 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Thursday, June 25th will be given a $0.24 dividend. The ex-dividend date of this dividend is Thursday, June 25th. This represents a $0.96 annualized dividend and a yield of 1.0%. Zimmer Biomet’s dividend payout ratio (DPR) is currently 24.94%.

Insiders Place Their Bets

In other Zimmer Biomet news, insider Sang Yi sold 5,000 shares of the firm’s stock in a transaction on Friday, May 29th. The stock was sold at an average price of $82.64, for a total value of $413,200.00. Following the sale, the insider directly owned 27,251 shares in the company, valued at approximately $2,252,022.64. This trade represents a 15.50% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 1.28% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. JPMorgan Chase & Co. reduced their price target on Zimmer Biomet from $100.00 to $95.00 and set a “neutral” rating for the company in a report on Wednesday, April 29th. Truist Financial reaffirmed a “hold” rating and set a $92.00 target price (down from $98.00) on shares of Zimmer Biomet in a report on Wednesday, April 29th. Citizens Jmp lowered their price target on Zimmer Biomet from $120.00 to $105.00 and set a “market outperform” rating for the company in a report on Wednesday, April 29th. Leerink Partners began coverage on Zimmer Biomet in a research report on Monday, April 13th. They set a “hold” rating and a $101.00 price target on the stock. Finally, Citigroup reduced their price objective on Zimmer Biomet from $95.00 to $93.00 and set a “neutral” rating on the stock in a research note on Thursday, May 28th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, twelve have issued a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $102.70.

Zimmer Biomet Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.